Drug intelligence / Profile preview

manpixiao

Development stage: Phase 1
Lead developer: Beijing University of Chinese Medicine
Administration: Oral

Overview

Manpixiao is a traditional Chinese medicine formula primarily used to improve gastric mucosal pathology and stomach discomfort in patients with gastric precancerous lesions. Research suggests it works through multiple mechanisms including anti-inflammatory effects and regulation of signaling pathways such as EGFR-PI3K-AKT. Studies have shown it can improve the pathological condition of gastric mucosa in precancerous lesion models and reduce inflammation-related cytokines.

Other names: Manpixiao Decoction

Targets

EGFR (Epidermal growth factor receptor)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on manpixiao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on manpixiao.

Explore the full profile